Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01089608
Other study ID # LT1225-PII-06/09
Secondary ID 2009-017388-41
Status Completed
Phase Phase 2
First received March 17, 2010
Last updated November 3, 2014
Start date March 2010
Est. completion date June 2012

Study information

Verified date October 2014
Source Laboratoires Thea
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).


Description:

Currently, topical antibiotic ointments are used for blepharitis. They provide prolonged contact time with the lid margin but with little penetration into eyelid tissue. Azithromycin eye drops may offer on advantage over these preparations because azithromycin achieves sustained high concentration in various ocular tissues including the lid margin.

Patients will be treated during 7 days (1 drop twice daily the first day following by one drop once daily for 6 days) following by a period of 2 weeks without treatment. This therapeutic scheme will be repeated two times.

Efficacy will be evaluated by change from baseline (Day 0) to Day 63 ± 3 Days of the global ocular discomfort evaluation (VAS).


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

-Diagnosis of moderate to severe chronic blepharitis (posterior and/or anterior) in at least one eligible eye

Exclusion Criteria:

- Monophtalmia

- Eyelid dysfunction

- Facial paralysis.

- Severe dry eye syndrome.

- Ocular metaplasia.

- Filamentous keratitis

- Schirmer test < 5 mm.

- Best far corrected visual acuity < 1/10.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin
Eye drops, Dosage : 1.5% 1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Povidone
Eye drops Single dose unit 1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.

Locations

Country Name City State
France C.H.N.O des XV-XX Paris

Sponsors (3)

Lead Sponsor Collaborator
Laboratoires Thea Keyrus, VEEDA

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale (VAS - Ranges 0-100 mm) The primary objective is to evaluate the efficacy of the treatment by the change from baseline (Day 0) to Day 63 (± 3 Days) of the global ocular discomfort (Visual Analogue Scale) (Decrease of VAS value = better outcome) Baseline and D63 (D63 minus baseline) No
See also
  Status Clinical Trial Phase
Completed NCT04475432 - Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis Phase 2/Phase 3
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05629390 - Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study Phase 3
Terminated NCT02938078 - Ocular Comfort and Inflammation in Lid Hygiene Therapy N/A
Completed NCT01408082 - Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis Phase 3
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Recruiting NCT04858113 - Short-term Effects on Tear Film (Baby Shampoo vs Blephasol) N/A
Completed NCT00560703 - Treatment of Patients With Blepharitis and Facial Rosacea Phase 2
Recruiting NCT02455895 - Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora N/A
Completed NCT00894530 - The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Phase 2
Completed NCT01115192 - Blephacura Versus Baby Shampoo to Treat Blepharitis N/A
Completed NCT02386774 - Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa N/A
Completed NCT01808560 - Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery N/A
Completed NCT00629590 - Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis Phase 4
Completed NCT00629941 - Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis Phase 4
Completed NCT03926026 - Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Phase 2
Recruiting NCT04603222 - Evaluation of SUMMIT BRUSH in Treatment of Blepharitis N/A
Completed NCT02218489 - Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Phase 2
Completed NCT00796926 - Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Phase 3
Completed NCT00803452 - Lipids of the Human Tear Film and Their Effect on Tear Stability Phase 4